NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

NW Bio To Present Updates On DCVax® Clinical Programs
In Industry Theater Presentation At ASCO
Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and
Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial

BETHESDA, Md., May 30, 2019 - Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit hall at the 55th Annual ASCO Convention at the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will deliver a webcast update on the Company’s clinical programs.

ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago. Over 30,000 medical professionals from all over the world attend to present and exchange information on the latest potential breakthroughs in cancer research and treatments.

Dr Bosch’s presentation will provide updates about the Company’s DCVax-Direct and DCVax-L programs. The DCVax-Direct updates will include follow-up data from the Company’s Phase I trial for all types of inoperable solid tumors, and plans for further trials.

The DCVax-L updates will include a progress report on the Company’s work on preparations necessary for unblinding of the Company’s Phase III trial of DCVax-L for Glioblastoma brain cancer.

Dr. Bosch’s presentation will be webcast live at: https://nwbio.com/update-on-dc-vax-at-asco-2019/ The presentation will also be available on the home page of the Company’s website (www.nwbio.com) after the ASCO conference ends.

The industry theater presentation will not be an official presentation of the 2019 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO® or Conquer Cancer®, the ASCO Foundation, and not CME-accredited.